The Future
is Synthetic
Nucleic acids for next-generation therapeutics and vaccines
Synthetic DNA, a transformative alternative
Providing you with a strategic advantage for vaccine and therapeutic development, eliminating bottlenecks and accelerating innovation in genetic medicine.
4x faster
Robust scalability
vs pDNA production, as little as 8 weeks
From discovery
to clinic
Purity
Enhanced safety
Efficient by
design
No bacterial sequences
Applications
With state-of-the-art, application-specific synthetic DNA solutions 4basebio have addressed the diverse requirements for therapeutic and vaccine development. You’ll reach proof of concept and subsequent clinical milestones faster and more efficiently while ensuring the highest safety and quality standards for your genetic medicines.
Improve your mRNA yields and simplify production workflows for mRNA vaccines and therapeutics.
Mitigate packaging of exogenous sequences, while achieving equivalent viral titers using less DNA input material.
Increase gene editing efficiency with dsDNA and ssDNA templates across a wide range of gene editing applications.
Latest news from 4basebio
01 JUL 2025 / PRESS RELEASE
4basebio introduces new branding to reflect next phase of growth enabling development of advanced genetic therapies
Today we introduced a refined visual system, including a modernised logo, refreshed colour palette, and a suite of new imagery. The Company’s redesigned website provides a more intuitive access point for partners and customers, providing detailed information and support for 4basebio’s expanding capabilities across synthetic DNA, mRNA, gene editing, and plasmid-free manufacturing.
06 MAY 2025 / BLOG
No bacteria, no bottlenecks: The future of DNA IVT templates is synthetic
The remarkable success of mRNA therapies and vaccines, highlighted during the COVID-19 pandemic, is revolutionizing modern medicine. Central to the production of these mRNA-based interventions is the DNA template used in in vitro transcription (IVT) reactions. Traditionally, plasmid DNA (pDNA) has been the foundation for such therapies.
02 APR 2025 / PRESS RELEASE
4basebio Plc - 4basebio Receives GMP Licence for its UK DNA Manufacturing Facility
Today we received Good Manufacturing Practice (GMP) certification from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). The licence enables the company to support our customers and partners in the fields of cell and gene therapy and vaccine development with GMP-grade synthetic DNA for their clinical programs.
Accelerate your timelines with GMP synthetic DNA
“With the right partner and a clear strategy, companies can unlock synthetic DNA’s benefits, de-risking manufacturing, reducing lead times and accelerating development milestones, while maintaining programme continuity and momentum.”